ImmunityBio's stock is moving higher after the FDA announced it would review a possible label expansion for the company's core Anktiva drug.

ImmunityBio (IBRX) added ~9% in the premarket on Wednesday after the U.S. Food and Drug Administration accepted its marketing application aimed at expanding the label of its bladder cancer therapy, ...

OTC appetite suppressants, natural weight loss pills, prescription vs OTC standards, and a 9-point consumer verification ...

Which chemicals and food production standards that are acceptable and common in foods in the United States are illegal in ...

European growth stocks are getting another look as investors search for earnings growth outside the usual U.S. mega-cap ...

Sarepta Therapeutics Inc (NASDAQ: SRPT) is one of the best gene therapy stocks to buy in 2026. Sarepta’s Q1 2026 report, ...

Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data ...

CDSCO seeks public to report violation of rules in cosmetics segment: Gireesh Babu, New Delhi Thursday, May 21, 2026, 08:00 ...

A federal court decision finding that sugar content does not make a beverage less "nutritional," a bill that would allow FDA to destroy imported ...

The FDA approved the aldosterone synthase inhibitor Baxfendy (baxdrostat) for adults with inadequately controlled hypertension.

Shares of ImmunityBio IBRX were up 3% in after-market trading yesterday after the company announced that the FDA accepted its ...

NeuroZen Scam or Legit, Consumer Complaints, Side Effects, Tinnitus Ear Health Ingredients, Does It Work, Pricing, and 60-Day ...